Insomnia – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Insomnia – Pipeline Review, H1 2017’, provides an overview of the Insomnia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Insomnia

The report reviews pipeline therapeutics for Insomnia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Insomnia therapeutics and enlists all their major and minor projects

The report assesses Insomnia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Insomnia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Insomnia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Actelion Ltd

Alexza Pharmaceuticals Inc

Athenex Inc

Eisai Co Ltd

Evotec AG

Grupo Ferrer Internacional SA

Heptares Therapeutics Ltd

Intec Pharma ltd

Intra-Cellular Therapies Inc

Johnson & Johnson

Leading BioSciences Inc

Merck & Co Inc

Neurim Pharmaceuticals Ltd

Novartis AG

Reviva Pharmaceuticals Inc

Shionogi & Co Ltd

Taisho Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Ltd

Yangtze River Pharmaceutical Group

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Insomnia - Overview

Insomnia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Insomnia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insomnia - Companies Involved in Therapeutics Development

Actelion Ltd

Alexza Pharmaceuticals Inc

Athenex Inc

Eisai Co Ltd

Evotec AG

Grupo Ferrer Internacional SA

Heptares Therapeutics Ltd

Intec Pharma ltd

Intra-Cellular Therapies Inc

Johnson & Johnson

Leading BioSciences Inc

Merck & Co Inc

Neurim Pharmaceuticals Ltd

Novartis AG

Reviva Pharmaceuticals Inc

Shionogi & Co Ltd

Taisho Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Ltd

Yangtze River Pharmaceutical Group

Insomnia - Drug Profiles

(diphenhydramine + lorazepam + zolpidem tartrate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-2810 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CY-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CY-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DORA-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVT-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-6641 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-48816274 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-7922 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LASSBio-785 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LASSBio-786 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lemborexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lorediplon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumateperone tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MLS-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nebivolol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-1940 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ramelteon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-117957 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit OX2R for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate CYP1A2 for Insomnia and Anxiety - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-142 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCM-765 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zaleplon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zaleplon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zolpidem tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zolpidem tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insomnia - Dormant Projects

Insomnia - Discontinued Products

Insomnia - Product Development Milestones

Featured News & Press Releases

Mar 02, 2017: Blake Insomnia Therapeutics and Sajo Consulting Introduce Clinical Trial Team Members

Feb 06, 2017: Ergomed announces positive Phase II top-line results of co-development partner Ferrer’s Lorediplon for the treatment of insomnia

Jan 17, 2017: Blake Insomnia Therapeutics Seeks Financing for Clinical Trials

Sep 08, 2016: Ergomed Completes Recruitment of Phase IIa Clinical Trial of Lorediplon in Insomnia in Collaboration with co-development Partner Ferrer

Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia

Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202

Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients

Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder

Dec 16, 2015: Intec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Zaleplon in Europe

Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202

Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist

Jul 14, 2015: Ferrer initiates phase IIa clinical study of Lorediplon in patients with insomnia

Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist

Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia

Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Insomnia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Insomnia – Pipeline by Actelion Ltd, H1 2017

Insomnia – Pipeline by Alexza Pharmaceuticals Inc, H1 2017

Insomnia – Pipeline by Athenex Inc, H1 2017

Insomnia – Pipeline by Eisai Co Ltd, H1 2017

Insomnia – Pipeline by Evotec AG, H1 2017

Insomnia – Pipeline by Grupo Ferrer Internacional SA, H1 2017

Insomnia – Pipeline by Heptares Therapeutics Ltd, H1 2017

Insomnia – Pipeline by Intec Pharma ltd, H1 2017

Insomnia – Pipeline by Intra-Cellular Therapies Inc, H1 2017

Insomnia – Pipeline by Johnson & Johnson, H1 2017

Insomnia – Pipeline by Leading BioSciences Inc, H1 2017

Insomnia – Pipeline by Merck & Co Inc, H1 2017

Insomnia – Pipeline by Neurim Pharmaceuticals Ltd, H1 2017

Insomnia – Pipeline by Novartis AG, H1 2017

Insomnia – Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Insomnia – Pipeline by Shionogi & Co Ltd, H1 2017

Insomnia – Pipeline by Taisho Pharmaceutical Co Ltd, H1 2017

Insomnia – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Insomnia – Pipeline by Yangtze River Pharmaceutical Group, H1 2017

Insomnia – Dormant Projects, H1 2017

Insomnia – Dormant Projects, H1 2017 (Contd..1), H1 2017

Insomnia – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Insomnia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports